E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
ITP diagnosis being defined by ASH-2011 and BCSH 2010 criteria adopting the new consensus terminology proposed by an international working group (Rodeghiero et al, 2009) |
|
E.1.1.1 | Medical condition in easily understood language |
treatment of Immune thrombocytopenia (a group of disorders characterized by autoimmune destruction of platelet and insufficient platelet production leading to an increased risk of bleeding) |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Blood and lymphatic diseases [C15] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 15.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10023095 |
E.1.2 | Term | ITP |
E.1.2 | System Organ Class | 100000004851 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the efficacy of I10E in increasing platelet count and controlling bleedings in patients suffering from primary Immune ThrombocytoPenia (ITP). |
|
E.2.2 | Secondary objectives of the trial |
To assess the biological and clinical safety profile of I10E. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Both genders
2. Age between 18 to < 80 year old
3. Chronic Primary ITP
- ITP diagnosis being defined by ASH-2011 and BCSH 2010 criteria adopting the new consensus terminology proposed by an international working group (Rodeghiero et al, 2009):
▪ Isolated thrombocytopenia diagnosed with platelet count
<100 x 10exp9/l and no abnormality of cells of other haematological
lineage and,
▪ Normal bone marrow (if available), or history of response to an
ITP treatment (corticosteroids, IVIg, anti-D) and,
▪ Failure to find any other causes of thrombocytopenia.
- Chronic ITP with bleeding(s) or an increased risk of bleeding:
▪ More than 12 months from diagnosis of ITP and,
▪ Platelet counts < 30 x 10exp9/l at the time of inclusion.
Note: Refractory ITP may be included and is defined by the failure to achieve a response or by the loss of response after splenectomy and the need of treatment (s) to minimize the risk of bleeding considered as clinically
significant by the investigator.
4. Written informed consent.
5. Patient is covered by health care insurance system. |
|
E.4 | Principal exclusion criteria |
1. Known hypersensitivity to the active substance or to any of the excipients.
2. Patient with IgA deficiency except if the absence of anti IgA antibodies is documented.
3. History of cardiac insufficiency (NYHA III/IV), cardiomyopathy, congestive heart failure, or severe hypertension (systolic blood pressure > or = to160 mmHg and diastolic blood pressure > or = to 100 mmHg).
4. History of thrombotic episodes (including deep vein thrombosis, myocardial infarction, cerebrovascular accident, pulmonary embolism) within the last 12 months in patients aged < 65 years and at any time in patients aged from 65 to 79 years.
5. Patient known to be infected with hepatitis B virus, hepatitis C virus, or human immunodeficiency virus.
6. Treatment that could induce thrombocytopenia within 15 days prior to inclusion.
7. Recent previous treatment, the action of which may interfere with the assessment of the investigational medicinal product:
- Initiation of corticosteroids or regular increase in the steroid dose within the last 4 weeks (EMA/CHMP/BPWP/94033/2007 rev.2),
- IVIg within the last 4 weeks,
- Anti-D within the last 4 weeks,
- Cyclosporin A within 4 weeks,
- Immunomodulator (as vincristin, vinblastin) within the last month,
- Immunosuppressor (azathioprine, cyclophosphamide) within the last 4 weeks,
- Anti-CD20 (rituximab) within the last 4 months,
- Antigonadotropin Hormone (danazol) within the last 6 months,
- Thrombopoietin receptors agonist (eltrombopag, romiplostim) within the last 4 weeks,
8. Splenectomy required during the study period or within the two previous months.
9. Severe haemorrhagic syndrome whether life-threatening or not, such as intracranial haemorrhage, gastrointestinal haemorrhage, gynaecological
haemorrhage with deglobulisation of more than 2g/dL or major cutaneous-mucosal haemorrhagic syndrome.
10. Severe bleeding or planned surgery requiring platelets transfusion at time of inclusion, or whole blood transfusion.
11. Plasma exchange 4 weeks before inclusion.
12. Concomitant disease that may induce a secondary immune thrombocytopenia, as:
- Clinical active systemic lupus erythematous with more than 4 American College of Rheumatology criteria,
- Lymphoproliferative disease or active malignant condition requiring antineoplastic or cytotoxic treatment.
13. Known hepatic disorder including total bilirubin > 2 x upper limit of normal range, alanine aminotransferase (ALT) or aspartate amino transferase (AST) > 3 x upper limit of normal range.
14. Prior episode of renal insufficiency or creatinine clearance values < 80 ml/min/1.73 m2 before inclusion (Modified Diet in Renal Disease calculation).
15. Medical history of haemolysis or haemolytic anaemia during prior IVIg therapy or any other concomitant disease of clotting system (i.e. haemophilia).
16. Administration of another investigational medicinal product within the last month.
17. Any serious medical condition that would interfere with the clinical assessment of I10E or prevent the patient to comply with the protocol requirements.
18. Pregnant with positive results pregnancy urinary test or breastfeeding woman, or woman of childbearing potential without effective contraception (effective contraception are: injectable, patch or combined
oral estro-progestative or progestative contraceptives, intra-uterine devices of type 'copper T' and levonorgest releasing IU systems, depot intramuscular medroxyprogesteron, subcutaneous implants of
progestative contraceptives implants, barrier methods of contraception: Condom or occlusive cap (diaphragm or cervical/vault caps) with spermicide, true abstinence (when this is in line with the preferred and usual lifestyle of the subject)).
19. Anticipated poor compliance of patient with study procedures.
20. Use of loop diuretics within a week prior the inclusion.
21. History of alcohol or drug abuse.
22. Previously included /enrolled in this clinical study.
23. Body mass index >= 40 kg/m2.
24. Risk factors for blood hyperviscosity such as cryoglobulinemia or hematologic malignancy with monoclonal gammapathy.
25. History of congenital or acquired thrombphilia
26. Factors contributing to venous stasis such as long-term bed confinement
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint is the number and percentage of patients with responses (including complete responses) during the investigational period.
Patients with response (R):
- Platelet counts > or = to 30 x 10 exp9/l and at least 2-fold increase of baseline platelet count confirmed on at least 2 separate visits at least 7 days apart.
- And absence of new bleeding.
· Patients with complete response (CR):
- Platelet count > or = to 100 x 10 exp9/l, confirmed on at least 2 separate visits at least 7 days apart.
- And absence of new bleeding. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
confirmed on at least 2 separate visits at least 7 days apart during the study period.
|
|
E.5.2 | Secondary end point(s) |
Efficacy criteria:
- Number and % of patients with complete response (CR) during the investigational period.
- Time to response i.e. time from starting treatment to time of platelet response achievement (platelet count > or = to 30 x 10 exp9/l) in the responder
population.
- Maximum platelet counts and time to reach the maximum platelet count.
- Number and % of non-responders patients (NR) during the investigational period.
- Number and % of patients with a loss of R and CR during the investigational period.
- Duration of response defined as the number of days from the first day of the response (CR or R) to the first day of the loss of response (CR or R).
- Number and % of patients with platelet count > or = to 50 x 10 exp9/l at Day 5, Day 6 and Day 7.
- Evaluation of pre-existing bleedings (Khellaf score and WHO score assessed at baseline, Day 2, Day 14 and Day 30) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
see details provided in section E 5.2. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 35 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
France |
Germany |
Hungary |
Italy |
Poland |
Russian Federation |
Ukraine |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
End of the study will be last patient last visit |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 7 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |